UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8373) 8373
Book Chapter (80) 80
Magazine Article (22) 22
Book / eBook (9) 9
Conference Proceeding (4) 4
Dissertation (4) 4
Web Resource (4) 4
Newsletter (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (6551) 6551
life sciences & biomedicine (6226) 6226
humans (5838) 5838
male (4557) 4557
animals (2965) 2965
phosphodiesterase inhibitors - therapeutic use (2633) 2633
middle aged (1772) 1772
female (1675) 1675
pharmacology & pharmacy (1672) 1672
erectile dysfunction - drug therapy (1578) 1578
sildenafil citrate (1492) 1492
phosphodiesterase inhibitors - pharmacology (1413) 1413
adult (1338) 1338
phosphodiesterase 5 inhibitors - therapeutic use (1329) 1329
piperazines - therapeutic use (1285) 1285
aged (1215) 1215
treatment outcome (1209) 1209
urology & nephrology (1167) 1167
phosphodiesterase (1166) 1166
rats (1028) 1028
erectile dysfunction (1014) 1014
sildenafil (996) 996
mice (851) 851
impotence (787) 787
purines (725) 725
abridged index medicus (722) 722
tadalafil (719) 719
sulfones (710) 710
analysis (673) 673
sulfones - therapeutic use (673) 673
cardiovascular system & cardiology (656) 656
drug therapy (656) 656
care and treatment (620) 620
hypertension, pulmonary - drug therapy (618) 618
dose-response relationship, drug (596) 596
disease models, animal (572) 572
nitric oxide (569) 569
research (562) 562
cardiac & cardiovascular systems (550) 550
double-blind method (542) 542
general & internal medicine (541) 541
neurosciences & neurology (539) 539
purines - therapeutic use (518) 518
neurosciences (512) 512
health aspects (507) 507
vasodilator agents - therapeutic use (507) 507
phosphodiesterase inhibitors - adverse effects (505) 505
phosphodiesterase inhibitors - administration & dosage (501) 501
pulmonary hypertension (501) 501
phosphodiesterase inhibitors (490) 490
risk factors (480) 480
drug therapy, combination (470) 470
erectile dysfunction - etiology (468) 468
respiratory system (467) 467
medicine & public health (458) 458
rodents (444) 444
piperazines - pharmacology (436) 436
time factors (422) 422
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (419) 419
cyclic amp - metabolism (414) 414
rats, sprague-dawley (411) 411
carbolines - therapeutic use (409) 409
inflammation (401) 401
medicine, general & internal (387) 387
proteins (384) 384
research article (383) 383
medicine (379) 379
biochemistry & molecular biology (378) 378
phosphodiesterase 5 inhibitors (375) 375
vardenafil dihydrochloride (373) 373
hypertension (365) 365
cell biology (362) 362
phosphodiesterase 5 inhibitors - pharmacology (362) 362
administration, oral (361) 361
cyclic nucleotide phosphodiesterases, type 5 (360) 360
enzymes (358) 358
phosphodiesterases (349) 349
cyclic gmp - metabolism (348) 348
piperazines - adverse effects (348) 348
imidazoles - therapeutic use (342) 342
rats, wistar (337) 337
3',5'-cyclic-gmp phosphodiesterases - antagonists & inhibitors (335) 335
clinical trials (335) 335
kinases (331) 331
signal transduction (331) 331
phosphoric diester hydrolases - metabolism (326) 326
science & technology - other topics (320) 320
multidisciplinary sciences (319) 319
penile erection - drug effects (313) 313
erectile dysfunction - physiopathology (312) 312
cyclic nucleotide phosphodiesterases, type 4 (308) 308
physiological aspects (308) 308
cyclic amp (298) 298
prospective studies (298) 298
cells, cultured (291) 291
physiology (291) 291
sexual disorders (290) 290
piperazines - administration & dosage (289) 289
dosage and administration (287) 287
internal medicine (285) 285
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8190) 8190
German (127) 127
French (65) 65
Japanese (64) 64
Chinese (61) 61
Russian (59) 59
Spanish (32) 32
Portuguese (31) 31
Italian (8) 8
Dutch (6) 6
Polish (5) 5
Turkish (3) 3
Bulgarian (2) 2
Czech (2) 2
Hebrew (2) 2
Hungarian (2) 2
Norwegian (2) 2
Danish (1) 1
Finnish (1) 1
Serbian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European journal of pharmacology, ISSN 0014-2999, 03/2006, Volume 533, Issue 1-3, pp. 110 - 117
...) and cyclic guanosine monophosphate (cGMP) into inactive 5′ monophosphates, and exist as 11 families... 
Phosphodiesterase inhibitor | Rolipram | Chronic obstructive pulmonary disease | Roflumilast | Cilomilast | Phosphodiesterase | Asthma | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Phosphodiesterase Inhibitors - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 4 | Nitriles - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 5 | Humans | Cyclopropanes - therapeutic use | Benzamides - therapeutic use | Aminopyridines - therapeutic use | Isoenzymes - metabolism | Anti-Inflammatory Agents - therapeutic use | Carboxylic Acids - therapeutic use | Benzamides - pharmacology | Carboxylic Acids - pharmacology | Cyclopropanes - pharmacology | 3',5'-Cyclic-AMP Phosphodiesterases - metabolism | Phosphoric Diester Hydrolases - metabolism | Anti-Inflammatory Agents - pharmacology | Asthma - enzymology | Phosphodiesterase Inhibitors - pharmacology | Clinical Trials as Topic | Asthma - drug therapy | Pulmonary Disease, Chronic Obstructive - enzymology | Animals | 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors | Aminopyridines - pharmacology | 3',5'-Cyclic-GMP Phosphodiesterases | Cyclohexanecarboxylic Acids | Cyclic Nucleotide Phosphodiesterases, Type 7 | Isoenzymes - antagonists & inhibitors | Nitriles - therapeutic use | Pulmonary Disease, Chronic Obstructive - drug therapy | Hydrolysis | Hypertension | Isoenzymes | Guanosine | Cyclic adenylic acid | Esterases | T cells | Adenylic acid | Cyclic guanylic acid | Index Medicus
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 05/2016, Volume 23, Issue 12, pp. 1239 - 1249
Journal Article
The Prostate, ISSN 0270-4137, 09/2013, Volume 73, Issue 13, pp. 1391 - 1402
.... Chronic inflammation is one of the putative links between these diseases. Phosphodiesterase type 5 inhibitors (PDE5i... 
metabolic syndrome | lipids | tadalafil | PDE5 inhibitors | inflammation | BPH/LUTS | prostate | vardenafil | Endocrinology & Metabolism | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Cyclic GMP - pharmacology | Inflammation - pathology | Sulfones - therapeutic use | Prostatic Hyperplasia - pathology | Triazines - therapeutic use | Lower Urinary Tract Symptoms - pathology | Humans | Middle Aged | Male | Sulfones - pharmacology | Prostate - metabolism | Myofibroblasts - metabolism | Prostate - pathology | Inflammation - metabolism | Cyclic GMP - analogs & derivatives | Lower Urinary Tract Symptoms - drug therapy | Inflammation - drug therapy | Aged, 80 and over | Prostate - drug effects | Interleukin-8 - secretion | Phosphodiesterase 5 Inhibitors - therapeutic use | Imidazoles - therapeutic use | Phosphodiesterase 5 Inhibitors - pharmacology | Carbolines - therapeutic use | Prostatic Hyperplasia - drug therapy | Myofibroblasts - pathology | Triazines - pharmacology | Double-Blind Method | Treatment Outcome | Imidazoles - pharmacology | Piperazines - therapeutic use | Myofibroblasts - drug effects | Piperazines - pharmacology | Prostatic Hyperplasia - metabolism | Tadalafil | Pilot Projects | Lower Urinary Tract Symptoms - metabolism | Vardenafil Dihydrochloride | Aged | Carbolines - pharmacology | Low density lipoproteins | Inflammation | Cholesterol | Index Medicus
Journal Article
Journal of sexual medicine, ISSN 1743-6095, 01/2013, Volume 10, Issue 1, pp. 130 - 171
...s: ED, phosphodiesterase type 5 (PDE5) inhibitors, oral drug therapy, intracavernosal injection therapy, transurethral therapy, topical therapy, and vacuum-erection therapy/constriction devices... 
Erectile Dysfunction | Phosphodiesterase Inhibitors | Vacuum Device Therapy | Oral Drug Treatment | Combination Therapies | Transurethral Alprostadil Therapy | Intracavernous Self-Injection Therapy | Intracavernous Self‐Injection Therapy | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Male | Alprostadil - therapeutic use | Erectile Dysfunction - therapy | Aged, 80 and over | Imidazoles - therapeutic use | Imidazoles - adverse effects | Risk Factors | Phosphodiesterase 5 Inhibitors - administration & dosage | Alprostadil - adverse effects | Yohimbine - adverse effects | Piperazines - therapeutic use | Sulfones - pharmacokinetics | Carbolines - administration & dosage | Piperazines - adverse effects | Sulfonamides - pharmacokinetics | Yohimbine - therapeutic use | Tadalafil | Vardenafil Dihydrochloride | Pyrimidines - pharmacokinetics | Hypogonadism - therapy | Triazines - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Triazines - pharmacokinetics | Piperazines - administration & dosage | Sulfones - therapeutic use | Age Factors | Triazines - therapeutic use | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Alprostadil - administration & dosage | Erectile Dysfunction - drug therapy | Penile Erection - drug effects | Adult | Phosphodiesterase 5 Inhibitors - therapeutic use | Piperazines - pharmacokinetics | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Pyrimidines - administration & dosage | Erectile Dysfunction - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Triazines - administration & dosage | Hypogonadism - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Carbolines - pharmacokinetics | Hypertension | Care and treatment | Conservatism | Online health care information services | Impotence | Prosthesis | Chronic diseases | Risk factors | Testosterone | Implants, Artificial | Prostaglandins E | Diabetes | Vasoactive intestinal peptides | Special education | Index Medicus
Journal Article
Journal Article
European heart journal, ISSN 0195-668X, 2014, Volume 35, Issue 40, pp. 2797 - 2811
Journal Article